中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2014年
10期
943-944,945
,共3页
药品不良反应%监测%统计%分析
藥品不良反應%鑑測%統計%分析
약품불량반응%감측%통계%분석
Adverse drug reaction%Monitoring%Statistics%Analysis
目的：了解广州开发区医院药品不良反应（ ADR）发生情况及引发ADR的相关因素，促进临床合理用药。方法：对该院2009-2013年收集的215例ADR报告分别从报告类型、患者年龄、给药途径、涉及药物种类以及临床具体表现等方面进行统计、分析。结果：215例ADR中，严重的ADR为15例（占7?0％）；青年患者较多，为119例（占55?4％）；静脉滴注引发的ADR为186例（占86?52％）；抗菌药物引发的ADR为118例（占54?88％）；ADR的临床表现以皮肤、黏膜及附件损伤为最常见，为120例次（占总例次数的42?86％）。结论：临床应提高ADR监测报告质量，加强抗感染药的合理使用，减少ADR的发生，保障公众用药安全。
目的：瞭解廣州開髮區醫院藥品不良反應（ ADR）髮生情況及引髮ADR的相關因素，促進臨床閤理用藥。方法：對該院2009-2013年收集的215例ADR報告分彆從報告類型、患者年齡、給藥途徑、涉及藥物種類以及臨床具體錶現等方麵進行統計、分析。結果：215例ADR中，嚴重的ADR為15例（佔7?0％）；青年患者較多，為119例（佔55?4％）；靜脈滴註引髮的ADR為186例（佔86?52％）；抗菌藥物引髮的ADR為118例（佔54?88％）；ADR的臨床錶現以皮膚、黏膜及附件損傷為最常見，為120例次（佔總例次數的42?86％）。結論：臨床應提高ADR鑑測報告質量，加彊抗感染藥的閤理使用，減少ADR的髮生，保障公衆用藥安全。
목적：료해엄주개발구의원약품불량반응（ ADR）발생정황급인발ADR적상관인소，촉진림상합리용약。방법：대해원2009-2013년수집적215례ADR보고분별종보고류형、환자년령、급약도경、섭급약물충류이급림상구체표현등방면진행통계、분석。결과：215례ADR중，엄중적ADR위15례（점7?0％）；청년환자교다，위119례（점55?4％）；정맥적주인발적ADR위186례（점86?52％）；항균약물인발적ADR위118례（점54?88％）；ADR적림상표현이피부、점막급부건손상위최상견，위120례차（점총례차수적42?86％）。결론：림상응제고ADR감측보고질량，가강항감염약적합리사용，감소ADR적발생，보장공음용약안전。
OBJECTIVE:To investigate the occurrences of adverse drug reactions ( ADRs ) and the associated factors of the ADRs in Guangzhou Development District Hospital so to promote clinical rational use of drugs. METHODS:215 ADR case reports collected in Guangzhou Development District Hospital during the period 2009-2013 were analyzed statistically in respect of types of ADR report, patients’ age distribution, route of administration, drug varieties and the specific clinical manifestation etc. RESULTS: Of the total 215 ADR cases, 15 ( 7?0%) were regarded as serious ones; 119 ( 55?4%) were young adults; 186 cases ( 86?52%) were induced by ivgtt; 118 (54?88%) were induced by antibiotics; 120 cases ( 42?86%) manifested as damage of skin and appendents. CONCLUSIONS:It is important to improve the quality of ADR monitoring and reporting and intensify and rational use of anti-infective drugs in order to reduce the incidence of ADR and ensure public medication safety.
